Semaglutide vs Retatrutide
A long-acting GLP-1 receptor agonist engineered for once-weekly dosing. An investigational GIP/GLP-1/glucagon triple receptor agonist. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Semaglutide | Retatrutide | |
|---|---|---|
| Also known as | Ozempic, Wegovy, Rybelsus | — |
| Type | Analog | Analog |
| Evidence | Established | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GLP-1 receptor agonist (acylated peptide, 31 aa) | GIP/GLP-1/glucagon triple agonist (acylated peptide) |
| Receptor | GLP-1 receptor (GLP-1R) | GIP + GLP-1 + glucagon receptors |
| Molecular weight | ~4,113.6 Da | ≈4,900 Da |
| Half-life | ||
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Semaglutide and Retatrutide?
- Semaglutide is an engineered analog based on Glucagon-like peptide-1; Retatrutide is an engineered analog based on Glucagon-like peptide-1. Semaglutide signals at GLP-1 receptor (GLP-1R); Retatrutide signals at GIP + GLP-1 + glucagon receptors.
- How do the half-lives of Semaglutide and Retatrutide compare?
- The reported circulating half-life of Semaglutide is ~7 days (~165 h); Retatrutide is ~6 days. These are reference values for the native or representative form — educational only, not dosing advice.
- Is Semaglutide the same as Ozempic?
- Ozempic, Wegovy, Rybelsus are brand names of Semaglutide. This comparison describes the molecules, not branded products.
Prefer the other order? Retatrutide vs Semaglutide. Or open the interactive comparison tool to add more molecules.